Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients

The prognosis of patients with advanced non small cell lung (NSCLC) cancer remains dismal. Epidermal Growth Factor Receptor is over-expressed in many epithelial derived tumors and its role in the development and progression of NSCLC is widely documented. CimaVax-EGF is a therapeutic cancer vaccine c...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Rodriguez, Pedro C, Neninger, Elia, García, Beatriz, Popa, Xitlally, Viada, Carmen, Luaces, Patricia, González, Gisela, Lage, Agustin, Montero, Enrique, Crombet, Tania
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2011
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3215653/
https://ncbi.nlm.nih.gov/pubmed/22024351
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1476-8518-9-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars